Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes

Cell Reports

Volumn 15, Issue 2, 2016, Pages 310-322

  Garcia Cuellar, Maria Paz ^a   Büttner, Christian ^a   Bartenhagen, Christoph ^b   Dugas, Martin ^b   Slany, Robert K ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Chromatin; DOT1L; Inhibitors; Leukemia; MLL ENL; P TEFb

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; HISTONE METHYLTRANSFERASE; PINOMETOSTAT; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN DOT1L; RNA POLYMERASE II; UNCLASSIFIED DRUG; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE FUSION; GENE TARGETING; GENETIC SCREENING; HISTONE METHYLATION; LEUKEMOGENESIS; ME3 GENE; ME5 GENE; MLL ENL GENE; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RNA SEQUENCE; TRANSCRIPTION TERMINATION; ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; SEQUENCE ANALYSIS; TUMOR GENE;

ANIMALS; CHROMATIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, NEOPLASM; MICE; ONCOGENE PROTEINS, FUSION; SEQUENCE ANALYSIS, RNA; TRANSCRIPTION, GENETIC;

EID: 84962110836     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.018     Document Type: Article

References (39)

1. Andersson A.K., Ma J., Wang J., Chen X., Gedman A.L., Dang J., Nakitandwe J., Holmfeldt L., Parker M., Easton J., et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 2015, 47:330-337. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.
2. Bach C., Buhl S., Mueller D., García-Cuéllar M.P., Maethner E., Slany R.K. Leukemogenic transformation by HOXA cluster genes. Blood 2010, 115:2910-2918.
3. Basavapathruni A., Olhava E.J., Daigle S.R., Therkelsen C.A., Jin L., Boriack-Sjodin P.A., Allain C.J., Klaus C.R., Raimondi A., Scott M.P., et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm. Drug Dispos. 2014, 35:237-252.
4. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
5. Campbell K.J., White R.J. MYC regulation of cell growth through control of transcription by RNA polymerases I and III. Cold Spring Harb. Perspect. Med. 2014, 4:a018408.
6. Chang M.J., Wu H., Achille N.J., Reisenauer M.R., Chou C.W., Zeleznik-Le N.J., Hemenway C.S., Zhang W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010, 70:10234-10242.
7. Chen C.W., Koche R.P., Sinha A.U., Deshpande A.J., Zhu N., Eng R., Doench J.G., Xu H., Chu S.H., Qi J., et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 2015, 21:335-343.
8. Dai Z., Dai X. Antisense transcription is coupled to nucleosome occupancy in sense promoters. Bioinformatics 2012, 28:2719-2723.
9. Daigle S.R., Olhava E.J., Therkelsen C.A., Basavapathruni A., Jin L., Boriack-Sjodin P.A., Allain C.J., Klaus C.R., Raimondi A., Scott M.P., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
10. Drygin D., Lin A., Bliesath J., Ho C.B., O'Brien S.E., Proffitt C., Omori M., Haddach M., Schwaebe M.K., Siddiqui-Jain A., et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011, 71:1418-1430.
11. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
12. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
13. He X., Arslan A.D., Ho T.T., Yuan C., Stampfer M.R., Beck W.T. Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis 2014, 3:e84.
14. Itzen F., Greifenberg A.K., Bösken C.A., Geyer M. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 2014, 42:7577-7590.
15. Jonkers I., Lis J.T. Getting up to speed with transcription elongation by RNA polymerase II. Nat. Rev. Mol. Cell Biol. 2015, 16:167-177.
16. Kanno T., Kanno Y., LeRoy G., Campos E., Sun H.W., Brooks S.R., Vahedi G., Heightman T.D., Garcia B.A., Reinberg D., et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. 2014, 21:1047-1057.
17. Lavau C., Szilvassy S.J., Slany R., Cleary M.L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997, 16:4226-4237.
18. Leach B.I., Kuntimaddi A., Schmidt C.R., Cierpicki T., Johnson S.A., Bushweller J.H. Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure 2013, 21:176-183.
19. Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
20. Maethner E., Garcia-Cuellar M.P., Breitinger C., Takacova S., Divoky V., Hess J.L., Slany R.K. MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep. 2013, 3:1553-1566.
21. Milne T.A., Martin M.E., Brock H.W., Slany R.K., Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005, 65:11367-11374.
22. Milne T.A., Zhao K., Hess J.L. Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol. Biol. 2009, 538:409-423.
23. Mohan M., Herz H.M., Takahashi Y.H., Lin C., Lai K.C., Zhang Y., Washburn M.P., Florens L., Shilatifard A. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010, 24:574-589.
24. Monroe S.C., Jo S.Y., Sanders D.S., Basrur V., Elenitoba-Johnson K.S., Slany R.K., Hess J.L. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp. Hematol. 2011, 39:77-86.e5.
25. Mueller D., Bach C., Zeisig D., Garcia-Cuellar M.P., Monroe S., Sreekumar A., Zhou R., Nesvizhskii A., Chinnaiyan A., Hess J.L., Slany R.K. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007, 110:4445-4454.
26. Mueller D., García-Cuéllar M.P., Bach C., Buhl S., Maethner E., Slany R.K. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 2009, 7:e1000249.
27. Pattabiraman D.R., Gonda T.J. Role and potential for therapeutic targeting of MYB in leukemia. Leukemia 2013, 27:269-277.
28. Pieters R., Schrappe M., De Lorenzo P., Hann I., De Rossi G., Felice M., Hovi L., LeBlanc T., Szczepanski T., Ferster A., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370:240-250.
29. Rahman S., Sowa M.E., Ottinger M., Smith J.A., Shi Y., Harper J.W., Howley P.M. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 2011, 31:2641-2652.
30. Roe J.S., Mercan F., Rivera K., Pappin D.J., Vakoc C.R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol. Cell 2015, 58:1028-1039.
31. Sánchez-Aguilera A., Arranz L., Martín-Pérez D., García-García A., Stavropoulou V., Kubovcakova L., Isern J., Martín-Salamanca S., Langa X., Skoda R.C., et al. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell 2014, 15:791-804.
32. Schreiner S., Birke M., García-Cuéllar M.P., Zilles O., Greil J., Slany R.K. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res. 2001, 61:6480-6486.
33. Shen L., Shao N., Liu X., Nestler E. ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics 2014, 15:284.
34. Slany R.K. When speed matters: leukemogenic transformation by MLL fusion proteins. Cell Cycle 2010, 9:2475-2476.
35. Stam R.W., Schneider P., Hagelstein J.A., van der Linden M.H., Stumpel D.J., de Menezes R.X., de Lorenzo P., Valsecchi M.G., Pieters R. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010, 115:2835-2844.
36. Stein E.M., Tallman M.S. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L. Curr. Opin. Hematol. 2015, 22:92-96.
37. Takacova S., Slany R., Bartkova J., Stranecky V., Dolezel P., Luzna P., Bartek J., Divoky V. DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo. Cancer Cell 2012, 21:517-531.
38. Wilkinson A.C., Ballabio E., Geng H., North P., Tapia M., Kerry J., Biswas D., Roeder R.G., Allis C.D., Melnick A., et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 2013, 3:116-127.
39. Zeisig B.B., Milne T., García-Cuéllar M.P., Schreiner S., Martin M.E., Fuchs U., Borkhardt A., Chanda S.K., Walker J., Soden R., et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 2004, 24:617-628.